For more information regarding Bristol Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Participants must have histologic confirmation of advanced (metastatic, recurrent,
and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall
cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per
RECIST 1.1
- Participants expected to have received standard of care therapies including an
available PD-(L)1 inhibitor
- Eastern cooperative oncology group performance status of 0 or 1
- Men and women must agree to follow methods of contraception
Exclusion Criteria:
- Participants with active, known or suspected autoimmune disease
- Participants with a condition requiring systemic treatment with either corticosteroids
or other immunosuppressive medications
- Uncontrolled or significant cardiovascular disease
- History of or with active interstitial lung disease or pulmonary fibrosis
- Prior participation in anti-NKG2A clinical study
- History of allergy or hypersensitivity to study drug components
Other protocol-defined inclusion/exclusion criteria apply
